Skip to content
DxDiagnoXpert
Patient lensAudience: patients

Lung Cancer

Cancers that begin in the lungs. NCI PDQ provides separate patient and clinician summaries covering types, staging, and treatment overviews.

Catalog review date: Oct 31, 2025

Open Trial Explorer

Suggested registry condition query: lung cancer

Overview

Patient-friendly

Lung cancer is a disease in which cells in the lung grow out of control. The two main groups people hear about are non-small cell and small cell. For accurate definitions, symptoms, and risk factors, use the NCI patient pages linked in Sources.

Professional

Refer to NCI PDQ for histology-specific overviews (NSCLC vs SCLC), epidemiology context, and evidence grading. This platform does not replace PDQ or institutional guidelines.

Sources

  • NCI Lung Cancer · National Cancer Institute (NCI) PDQ — Patient · retrieved Nov 13, 2025 · reviewed Oct 31, 2025
  • NSCLC HP PDQ · National Cancer Institute (NCI) PDQ — Health Professional · retrieved Nov 13, 2025 · reviewed Oct 31, 2025

Diagnosis and pathology

Patient-friendly

Diagnosis usually involves imaging and tissue sampling (biopsy). Pathology reports describe the cancer type. Ask your care team to explain your report in plain language.

Professional

Workup and pathology classification follow evolving WHO/IASLC frameworks as summarized in NCI PDQ and primary literature. Molecular testing indications are detailed on NCI HP pages—not reproduced here.

Sources

Staging and biomarkers

Patient-friendly

Staging describes how far cancer has spread. Biomarker tests look for changes that may guide treatment options. Results should be reviewed with your oncology team.

Professional

Staging systems and biomarker panels (e.g., EGFR, ALK, ROS1, BRAF, MET, RET, KRAS, PD-L1) are covered in NCI PDQ and society guidelines. DiagnoXpert does not assert eligibility for any targeted therapy.

Sources

General treatment approaches

Patient-friendly

Treatment may include surgery, radiation, medicines (including chemotherapy, targeted therapy, or immunotherapy), or combinations—depending on type and stage. Only your clinicians can recommend a plan for you.

Professional

Modality selection is stage-, histology-, and biomarker-dependent. Consult current NCI PDQ treatment options and institutional protocols. No treatment algorithm is authored here.

Sources

  • NSCLC treatment patient PDQ · National Cancer Institute (NCI) PDQ — Patient · retrieved Nov 13, 2025 · reviewed Oct 31, 2025
  • NSCLC treatment HP PDQ · National Cancer Institute (NCI) PDQ — Health Professional · retrieved Nov 13, 2025 · reviewed Oct 31, 2025

Relevant clinical trials

Patient-friendly

Clinical trials test new approaches. Use the DiagnoXpert Trial Explorer to search ClinicalTrials.gov. Matching a search is not the same as being eligible.

Professional

Query ClinicalTrials.gov (and optionally NCI CTS in Phase 2) by condition and biomarker terms. Verify enrollment with study teams.

Sources

Research and approvals

Patient-friendly

New research and medicine approvals appear regularly. Check the Updates page and official FDA/NCI announcements linked there.

Professional

Track FDA oncology approvals and NCI announcements via the Updates adapters (Phase 2 automation planned).

Sources

Patient resources

Patient-friendly

NCI offers educational materials, support organization links, and help finding care. Start with the NCI lung cancer hub.

Professional

Point patients to NCI.org resources; avoid duplicating third-party proprietary content.

Sources

  • NCI Lung Cancer resources · National Cancer Institute (NCI) PDQ — Patient · retrieved Nov 13, 2025 · reviewed Oct 31, 2025

Primary references

External evidence above is distinct from any future platform-authored clinical interpretation (which would require editorial review).